TransVision Madrid 2025 Summit

Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Greetings and welcome to the United States Transhumanist Party Virtual
Enlightenment Salon. My name is Jannati Stolier of the Second
and I am the Chairman of the US Transhumanist Party.
Here we hold conversations with some of the world's leading
thinkers in longevity, science, technology, philosophy, and politics. Like the

(00:21):
philosophers of the Age of Enlightenment, we aim to connect
every field of human endeavor and arrive at new insights
to achieve longer lives, greater rationality, and the progress of
our civilization.

Speaker 2 (00:39):
Aging is a natural process, but it's a process which
both our health and wealthy.

Speaker 3 (00:47):
We are lucky to have longevity researchers developing rejuvenation therapies.

Speaker 4 (01:17):
Welcome to Transvision twenty twenty five.

Speaker 5 (01:28):
Now let's move into a real investor.

Speaker 6 (01:31):
A real investor.

Speaker 5 (01:32):
You know, I have known Angel Versetti and what he
has been doing with his family office and also Dodge
dot org. And he has a lot of things to
say about how big this industry is, what will happen
in terms of investment possibilities, venture capital, and where we
are going to go with the longevity industry.

Speaker 6 (01:55):
So let's welcome Angel.

Speaker 2 (02:05):
Thank you everyone, it's a pleasure to be here in
the beautiful city of Madrid. So my presentation is titled
some Candidate Raw thoughts on the state of longevity as
an investment. So it's thoughts a lot of them and
through the prism of our experience as an investor and
their candidate, meaning that we want to be bullish, but
then there are some challenges we need to acknowledge.

Speaker 7 (02:25):
So I decided to use the quote here.

Speaker 2 (02:28):
From a Spanish writer and philosopher, Miguel de Unamuno. I
hope I'm pronouncing it correctly. That explains my style, which
is minimalistic. I think post child GPT raight. Far too
many fanciful designs out there, so I try to focus
on the content and briefly about my journey. I'm a
serial entrepreneur, having exited four different companies, two of them
became unicorns in Web three and II domains. I also

(02:50):
owned dosh dot org, which became the first online community
for doshcoin, which became one of the most famous cryptocurrencies
in the world.

Speaker 7 (02:57):
So I host the forum where the.

Speaker 2 (03:00):
First pictures of the dog were shared, and that would
have been a joke, but that joke turned out to
be nearly one hundred billion dollar market cap thing. So
there was a nice joke, and as of this year,
we've decided to focus entirely on longevity in terms of
our new ventures. Although I have been in the community
in various forms as an investor, grant making organization, and
an entrepreneur for about five and a half years since

(03:22):
the early days of COVID. So just a few clarifications,
it's difficult for us to define what exactly we are
because we're not really a VC. Here, you have some
you know, what's scratched is what a typical VC is like,
and what's written is what we have. So a venture
capital fund will typically have money from limited partners as
people who give money to the VC to invest. Therefore,
their mandate tends to be fixed because when you promise

(03:44):
someone to invest their money in a certain way, you
kind of have to stick to your promise. A lot
of VC funds have a particular timeline through which they
have to return their money to the investors. That makes
a lot of them sure to meetium term, and that
is not a problem in many industries like software, but
that is a problem for the space like longevity, which
requires much longer timeframes of investment a lot of the

(04:05):
funds that I have met.

Speaker 7 (04:06):
It's my opinion.

Speaker 2 (04:07):
I'm sure they will disagree, but I felt that they
spray and pray, meaning that they invest in a bit
of everything, but they don't have a particular like conviction bets,
and they tend to source a lot of deals externally.
In our case, the capital is our own, therefore the
mandate is flexible.

Speaker 7 (04:21):
We can afford to be long term and we are.

Speaker 2 (04:24):
Happy to support radical moonshots that move the needle. And
we also have the venture builder approach of which I
will talk about later. So we're also not a typical
family office, because family offices tend to be conservative and defensive.
Their goal is to preserve their wealth rather than grow it.
As a result, they tend to be diversified and passive allocators.

(04:44):
In our case, we're entrepreneurial. We're happy to take risks,
sometimes not too happy and when the results are not
that great, but that's what we're in for. I guess
we are focused on wealth growth for ourselves and for
the industry generally. Therefore, we make concentrated bets, whereby we
have a lot of skin game and we push the
companies to really focus on being operationally viable and commercially viable,

(05:05):
and we are a hands on operator, meaning that we
like to be very actively involved with our investments. I
would say around ninety to ninety five percent of family
offices do not operate this way. Therefore, I'm not even
sure if the name family office is correct for us.
And when I started just researching longevity, I read a
bunch of books by some of the most famous people
in longevity, and if I were to summarize them in

(05:25):
five small bullet points, most of them just said eat well, exercise,
good sleep, no stress.

Speaker 7 (05:31):
No bad habits.

Speaker 2 (05:32):
And while I'm like, Okay, why do I need all
these Harvard PhDs and Stanford professors and whatnot to really
tell me what I knew since I was a kid,
what my parents told me to do. Moreover, when I
researched a be deeper into the history of longevity, there
was an ancient Chinese philosopher and physician Gihong who said,
even if one performs breathing exercises and strength training as

(05:53):
well as in herbal medicines, this can only extend the
years of your lifespan, but it will not save you
from death, So that guy knew about it two thousand
years ago, and we're still like just repeating the same stuff,
and we're still struggling in the same way. Although of
course my personal response to that is that thankfully today
we have so many technological advancements so that hopefully we

(06:14):
can move beyond pure wishful thinking. So general, my thesis
is that longevity is hard. There are a number of
reasons that we've identified through our research. Again, these are
mostly opinions. I mean, there are many kind of anecdotal
stories or specific backing them, but these are mostly my thoughts,
so don't take them as facts. But it feels that
their market is still immature and fragmented. People are still

(06:36):
fighting about like what the definition of longevity should be.
I know it was a big subject of discussion at
this year's ARDD in Copenhagen. And therefore, if you don't
have even the universally accepted definition, of course, is difficult
for regulatory frameworks and standards to be developed, so they're
either poorly developed or non existent. They feel this multi
dimensional and highly complex, and I would say there are

(06:58):
two big chunks of participants when I look at it
from the business perspective. On the one side, there are
I call them hypocrite hygh writers. These are businesses that
don't really care about longevity, but they use the word
because it's an attractive investment term. And on the other side,
I mean, I call them like fanatic dreamers. They religiously
believe in longevity, they believe in the necessary to radically

(07:19):
increase lifespan and so on.

Speaker 7 (07:21):
But they are just like they're focused.

Speaker 2 (07:23):
On it like a religion, and you need to find
some golden means, some middle ground, and then of course,
I mean it's a no brainer. But biology itself is hard,
and I say that as a non biology guy coming
from a different background, and of course that's you know,
there are many examples where it's not just easy to
predict what's going to happen. So longevity startups are also hard.
So when we extrapolate from that to startups in particular, that's.

Speaker 7 (07:45):
What we're focused on.

Speaker 2 (07:46):
So a lot of them have again that's you know,
what our assessment is from our scientific and due diligence teams,
but they frequently lack clinical depth on clinical guidelines diverge
from country to country, so that's difficult for them to
be comparable to each other. Of course, a lot of
them have unsustainable margins and economics. We have observed a
number of high profile failures where when we try to

(08:07):
analyze what exactly did the team go wrong when the
company went bankrupt, there was not like particular reason, It
was not like an obvious failure or mistake, just the
economics didn't work. There are cases of longevity clinics that failed,
There are cases of companies that are biotech that failed,
and a number of others. So the graveyard of startups
in longevity is huge. A lot of startups engage in

(08:29):
misleading marketing, which leads to low consumer trust when they
make some huge statements and the over promise that leads
to the negative perception of the industry by the media
and by some of the consumers. It's oftentimes hard to
measure impact and outcomes, especially when you deal with human lifespan,
which you know is obviously multi decade long. So how
can you meaningfully prove to people that it can work

(08:51):
amongst a lot of users? There is poor retention and
follow through, so a lot of people that typically are
excited to start it out, to try it out, to
do the procedures or take.

Speaker 7 (09:00):
Whatever supplements or some other you know, more more.

Speaker 2 (09:03):
Advanced interventions, but they typically there's very low follow through,
so it's almost a cliff when we identified a number
of startups from their first client or first you know
intervention to the next one. And then generally within the
market context sees a lot of longevity companies overlap with biotech.
There is generally a biotech downturn, so it's at historical
lows over the past couple of decades, so that leads

(09:24):
to scarcity of capital. And on the next slide, I'm
sharing a few quotes from a few people. I tried
to make it a semi anonymous because some of these
conversations were just private or chatter and rule, but I
found it to be interesting. And these conversations are all
from the past three four weeks, by the way.

Speaker 7 (09:41):
So.

Speaker 2 (09:42):
Both from a CEO of a public company who said
we had to pretend to be a biotech company for
our i PO and not talk about longevity or else
the markets would freak out. Then I talked to a
fund who also says we promised to our LPs to
allocate to conservative pharma place and just a little bit
to longevity because otherwise we struggle to raise money. Another
startup company said we target disease X rather than aging

(10:05):
to look more credible to investors. And lastly, a you
know researchers said, we pretend not to work on radical
longevity because we don't want we want to continue receiving
research grants. And they also said, we don't want to
a random religious fanatic to come and shoot us. So
these are all real like quotes from pretty serious companies,
people or funds I've met. So it's a lot about perception,

(10:25):
how the investors perceive it, so we need to change
the narrative and the perception amongst the investors. And then
the last bit also of course, talks about personal safety
of some people who are working on more radical aspects
of longevity. And I met quite a few people who
prefer to stay in stealth, for example, because they are saying,
I'm not sure you know if somebody might come and
try and shoot us. So these are definitely So the

(10:45):
previous conversation about the necessary necessity of lobbying definitely is
important than just generally engaging media, the public opinion and
so on is equally important. So yeah, when I was
interviewed after ARDD like, so what's your conclusion from a
R I said, well, I guess we're all going to die.
So there is a lot of you know, like, there

(11:06):
is a lot of course progress. But then at the
same time, as at LBF whom someone mentioned today, the
Longevity Biotech Fellowship in which I participated, their you know,
their main argument is that as of today, there are
zero credible, credibly verifiable like longevity interventions on the market,
and it's important to be aware of that that this

(11:26):
is you know, we still have a lot of things
to go. But you know, I was asked to be
optimistic for this presentation.

Speaker 7 (11:33):
Therefore, let me.

Speaker 2 (11:34):
Say why I am here and not just like giving
up and left. I think the market opportunity for longevity
is definitely there. I was asked to prepare like estimates
of the market size and so on.

Speaker 7 (11:42):
I didn't want to give random numbers. I'm not a
fan of that.

Speaker 2 (11:46):
So I couldn't find any credible estimates of the market.
And not least because well, when you have no definition
for what kind of market you're talking about, it's hard
to find an estimate. So I have seen various attempts
to extrapolate to biotech space or set up peutics.

Speaker 7 (12:00):
Or farm or healthcare.

Speaker 2 (12:02):
I definitely am not the best person to judge which
of those is suitable.

Speaker 7 (12:07):
But importantly there are here on champions.

Speaker 2 (12:09):
Like from the previous quote I showed you the company
that is a public, publicly tradable company that has to
pretend to be just we're a normal biotech or we're
a normal pharma company. They are actually the head on
champions of longevity. And hopefully when it becomes more acceptable
for the public and investors to support the notion of
increasing lifespan and health span, they can be more open

(12:30):
about it and that can create a snowball effect. Secondly, well,
I think there's just generally speaking, an infinite market size
because who does not want to be healthier?

Speaker 7 (12:38):
Like if lifespan.

Speaker 2 (12:40):
Extension is maybe there are more people who could argue
about that. I don't think there's barely anyone in the
world who would not want to be healthier generally, so
the health span part of it is a no brainer.
The whole planet is your market when it comes to
like living longer and so on. Again, I'm a historian
by background, actually, so I just observe that like from
the historical perspect from the times of pharaohs of ancient

(13:02):
Egypt and the ancient kings and the emperors to the
wealthy leads of today, a lot of them always sought immortality,
They sought extension.

Speaker 7 (13:11):
Model of lifespan and so.

Speaker 2 (13:12):
On is deeply embedded into almost all religions, philosophies or folklore.
The first written kind of like story, the book the
novel Gilgamesh, you know that we have in the current
like scnsidicly, the first book written that has stayed until
the modern times. It deals with questions of seeking, you know, immortality.

(13:34):
So therefore that leads to a lot of I want
to believe investors, the optimist investors. Some of them come
from fields such as crypto or AI, and there have
been discussions that there are dreamers in a way, but
it's important to have investors who are dreamers, who are
not just like conservative, careful people looking for basic things.
And I also think that a acceleration definitely brings hope

(13:56):
for a lot of longevity challenges. So when people said
these trials can take long, we're you know, simulating a
certain kind of research can take longer, and so on.
There is some degree of hope there, although I have
also met a lot of people say so many things
in biology can't really be meaningfully you know, accelerated using AI.
And generally I'm also you know, generally looking at cycles
in the markets. So when something is at the bottom,

(14:18):
and biotech is set by everyone to be at the bottom,
then that tends to rise.

Speaker 7 (14:23):
And investors are always.

Speaker 2 (14:24):
Looking for a good bubble, like it's just like people
always want something that the narrative is there, and then
they creates a snowball effect. And we are currently in
the AI bubble obviously, but maybe the next one will
be a longevity bubble. So briefly about our approach, so
we tuck all this so since I mentioned that we're
neither a VC fund nor a proper family office, so
we take the approach of a longevity venture builder. So

(14:46):
our goal is to find this promising very early stage
startups or pre startups that try and move the needle
on lifespan or health spun. We want them to be
R and D and science or even not marketing things.
So it's you know, there are plenty of others who
can support marketing place, but we look for the evidence
back to scientific projects and that are grounded in commercial reality,

(15:07):
and therefore we're looking for such collaborations. We're actively exploring
them now with universities and with entrepreneurship groups. As mentioned,
we are an investorpreneur, so we are both investors and entrepreneurs.
We try and be the founding partner and help startups
to really focus on their operations, scaling and business growth.
That's something that most vcs that I talk with, given

(15:29):
that they have forty fifty companies in their portfolio, you
can't meaningfully grow forty fifty companies in parallel. Even doing
four or five companies in parallel is extremely hard. And
therefore we want to focus on like a small group
of superheroes. And yeah, we commet our own capital, and
then I am working with a number of other family
offices where I know that the principles or the family

(15:50):
members themselves have a personal interest in this space. I
like to remind the projects I work with about what
investment actually means. A lot of them tend to just assume, Okay,
doing longevity is good for humanity, and therefore you owe
me money. I think that's the wrong approach, and I
always try and like say either you know, you should
say you're a research organization and that's fine, but if
you're a startup, you should have a commercial model. You

(16:12):
should be able to explain to your investors are going
to bring money to them. I know it sounds like
why is this guy explaining this? But like so many
companies I meet, somehow just totally ignore that. And Yeah,
the questions that we ponder upon very often. So what
niches of longevit are worth investing in, how to do
risk or discard a project with minimum losses? How to
achieve both impact and profitability. It's important because we want

(16:34):
to do both. Ideally, how to predict the future behavior
of founders, that's a general startup question, not only for longevity.
And then how to navigate the whole geopolitics and focus
on progress and in today's world, unfortunately politics are messy,
a lot of popularism and at least to lack of
scientific collaboration oftentimes on top of a lot of stigmas
that longevity itself still has today. So that is something

(16:55):
we ponder upon, so that instead of you know, saying
it's not possible to reach the stuffs and forever, we
will add a yet that we can make it happen.

Speaker 6 (17:05):
Thank you.

Speaker 5 (17:16):
Wow, Angel, that was a powerful presentation, really fantastic. You
covered most of everything we wanted to have in this session.
We are very excited to have this panel to talk
about public advocacy and what different people are doing in
terms of advocacy. And each one will introduce themselves better

(17:38):
than I can introduce them, So it is I think
much much better to hear from them what they're working on.
We just had a little session to know what they
are working on, and then we will have some questions
and debate a little bit in the panel. Okay, so
let's begin now that we have everybody uh sitting in

(18:03):
their place, and each one has a different perspective on
what they are doing and public advocacy for longevity, but
they are all committed to longevity and biological rejuvenation. So
let's begin with Carmen Simon. Matteo, you have a microphone.
You need to turn in green. Now is red. Once

(18:23):
it is green, you can talk.

Speaker 6 (18:25):
Please, Thank you. An applauch to Carmen.

Speaker 8 (18:31):
So good good afternoon to everyone.

Speaker 9 (18:35):
First, I'm going to introduce myself, So I'm Carmen Simon.

Speaker 8 (18:40):
I'm a scientist.

Speaker 9 (18:42):
I work in the National Center for Biotechnology, which belongs
to the highest public research institution.

Speaker 8 (18:48):
In Spain, which is called.

Speaker 9 (18:51):
Spanish National Research Council, and I do research. I'm a virologist.
I work in plan virus. But I'm here because, as
to have seen before, I found more than ten years
ago I founded an association which is called a paternal Latentsia.

(19:13):
Only with the name you already know something about it.

Speaker 8 (19:17):
And we put.

Speaker 9 (19:18):
That name A Patrina latentia because we do care about
science and we do care about the investment in science.

Speaker 8 (19:25):
So a Vadrina Latentia is a.

Speaker 9 (19:27):
Place that has different parts of interest and along the
journey maybe I can explain to you later what do
we do. But the main idea is that we want
society and also the government's understand that investment in science

(19:49):
is very very important because finally all the results we
got with our research, with our investigation finally impact in society.
Of course, here in this meeting about longevity, so only
we can increase in longevity and also the well being
of people by doing research, So the investment has to

(20:12):
be there, but also we want to really diffuse in
the society the results we got in our investigations. And
also not less important is that we are very worried
because our kids and or young people don't want to
be scientists, and this is really very very.

Speaker 6 (20:31):
Tough to know.

Speaker 9 (20:32):
And we want to promote the vocation of these people
to be interested in doing science.

Speaker 8 (20:39):
So that's more or less the main ideas I.

Speaker 9 (20:42):
Wanted to show with to share with you in the
beginning of my talk.

Speaker 5 (20:49):
Thank you, thank you very much, Carmen. So now let's
go in a different perspective and Serchio will give us
a few ideas of what he's doing to advance longevity.

Speaker 10 (21:00):
Cercio, Okay, yeah, I think it's best that we introduced
ourselves briefly first and then a little longer because we
have a lot of time. So my name is Sergio
Martinez Ralga Taretro. I've been in the community, in the
longevity community for about twenty years. Twenty two years. I
met has recording a conference like this in Helsinki in
two thousand and six, so that's nineteen years ago, and

(21:22):
I've covered many conferences. I really like documenting these events.
I think they're historical and worth preserving. And I've got
involved with the community too to help make the ideas
rich wider audiences. It's still kind of unfortunate that it's
not more widespread, like Coovery said in his remarks, and

(21:43):
my main contribution, I think to the community was founding
the first plashunist political party in the world, Aljanha Patrista
Alpha in now twelve years ago, almost to the date.
It's the seventh of October, that's our anniversary. And exactly
a year later, the Transformitist Party the US was founded,
which was just chance, and we've basically brought this movement

(22:10):
to existence, having a political movement around transhumanism, both the
Allianta Patrista here in Spain and the Transumitist parties which
were founded in first in the US and then another
one in England I believe. I don't know if that's
still going, but yeah, I will advocate for much more
public investment on longevity science, obviously, which we also do

(22:31):
our march to push for. But I will talk a
little bit more about the party in a few minutes.

Speaker 6 (22:36):
I'll let the.

Speaker 5 (22:37):
Next person, beautiful, thank you. Actually we heard first a biologist,
second assysicist by training, and now we have Clara tell us,
how about you.

Speaker 11 (22:49):
My experience is an innovation healthcare. Hello everyone, Clara Claire Fernandez.
I am the longevity clinic in Valencia that Anhel was
talking about. Because last week Angel d Lan Aubrey, Natalie Ines,
a lot of the scientists and biotech longevity biotech community,
we're in my clinic. I hosted the Longevity Biotech Fellowship.

(23:13):
My clinic is in Valencia, and I'm going to be
talking about how the unique ecosystem and the unique model
that we have built and how what is our perspective
on how to democratize the access of longevity to society.
Just as a little bit of an introduction, we are
quite a bit clinic. We have an average of six
hundred patients per day that stay with us for ten days,

(23:35):
which has enabled us to create a unique model of
delivering longevity treatments at a very efficient skill. One of
the key elements that I'm going to also be talking
about is the importance of collaboration between longevity clinics and
the clinical scientific community. As most of the bank Guard
treatments are happening in longevity clinics, we need to make

(23:58):
sure that those data are analyzed and are translated to science,
so we can keep supporting what's happening and publish it
in scientific papers.

Speaker 6 (24:08):
Thank you so much, Clara.

Speaker 5 (24:10):
So let's hear from Carlos that also travels all the
time and here's doing many things, not just in Spain,
but all over Latin America.

Speaker 12 (24:20):
Thank you so much for inviting me. Thank you so much,
because Luis is always a pleasure. Also from that, I'm
very honored. I'm amazed by a number of people that
have been here over the last few days. I'm also
very thankful to my peers in this pandel because I've
been hearing from them a few minutes ago. I'm very pressed.

(24:41):
So my name is Carlos Ruta. I've been in this
sector for thirty nine years. I basically do a couple
of things. I am for profit investor, so I'm invested
in more than eight hundred and fifty.

Speaker 13 (24:52):
Projects all over the place.

Speaker 12 (24:54):
As you said, this is for profit but not for profit,
which is my most enthusiastic piece of the cake. I'm
also an investor in developing what I have denominated digital
health cities. And you would be guessing or thinking.

Speaker 13 (25:11):
What is that about. Well, this is my interpretation.

Speaker 12 (25:16):
It is only our interpretation of what we mean by that,
but basically we create spaces. So we have in Madrid.
We launch in Madrid on the fifth of June, the
first digital city worldwide. We have two campuses. Campus one
is Last marthadis eighty thousand scare meters and Campus two
is San Fernando more than one hundred thousand scare meters.

Speaker 13 (25:37):
And what do we do there.

Speaker 12 (25:38):
Let me first very quickly remind everyone that this is
the only sector in which the consumer, which is called patient,
is not a decision maker. Let's keep this in mind.
So I want to buy an iPhone, I go to
the shop and I buy my iPhone. I'm the decision maker,
I'm the payer, I'm the user. But in this market,

(26:00):
I am the patient. But remember, there is a doctor
who prescribes, there is someone called pharmacist who dispenses, and
then there is someone called insurer or government who pays
for this party, especially when we are talking about prescription.
And then I'm the patient. I'm using these medicine medical men.

(26:20):
So five six, seven stakeholders for one fact. So what
we do in these cities is interesting. First, we put
together public and private. This is vital, this is critical.
This is the neurological bit of everything we do. And
once we put together public and private sectors, we put

(26:41):
together a chemist with a doctor, with an association, with
a foundation, with a laboratory, with a distributor, and we
make things happen in those cities.

Speaker 13 (26:51):
So our advocacy, as we.

Speaker 12 (26:54):
Were meant to say as part of this panel, is
we am not an expert as my peer in longevity.
I must admit actually I was a very very bad student,
if I recall.

Speaker 13 (27:07):
But what we do is different.

Speaker 12 (27:09):
We try and do something which is in our view necessary,
which is melting together from the entrepreneurship side of things,
all of these people who are enthusiastic and are part
of this ecosystem into one discussion, so we integrate. I
would say, we are integrators, and that's how I would

(27:31):
put it. And then over the next few minutes we
will be talking more about some of the details.

Speaker 6 (27:36):
Thank you, Thanks to you, Carlos.

Speaker 5 (27:38):
And now let's hear from Marianna that I have the
pleasure to know her for over ten years since the
beginning of Rather First, which is the biggest global event
on longevity revolution against agent and death.

Speaker 14 (27:54):
So Marianna and wow, yeah, thank you for the invitation.
Thank you for having this space, thank you for bringing.

Speaker 15 (28:03):
All these people together.

Speaker 14 (28:05):
So I will be talking to you about two different
arms to different organizations and not for profit and non profit.
And the first one it's what you just mentioned, which
is what brought us together and how we met and
how I've met a lot of you and a lot
of the people that have spoken this weekend. It's the
Coalition for Radical Ethe Extension. It's been and not for
profit created about eleven years ago, and then its main

(28:30):
mission was to bring together and bridge the gap between
scientists and non scientists. So yesterday doctor memmoth Can and
then several of the speaker since then has spoken about
how important and bitle it is to bring non scientists
together with scientists. And that's what RADFST has been very
successful at. We've created and launched and helped and aid

(28:52):
a lot of collaboration between scientists and also bring their
science into the forefront for the people that are actually
the consumers, the people like us, the people that are
sitting here who want these technologies that they need to
know that these are happening, and also people doing the
public advocacy, like I have some people here and Dylan
also as well. And then the People Unlimited is and

(29:16):
not for it's a profit organization, and that is being
the longest standing and most active and most successful community
for individuals who are interested in super longevity and what
they do and what we've done, and I've been a
member for eighteen years. It's to bring people that are
mostly non scientists, but bring them together and to create

(29:37):
spaces of education and inspiration. And really it's been transforming
for all of its members and all the speakers. Actually,
Liss Perish gave her first presentation right after she got
hur gene therapy done first People Unlimited because she was
recommended to it. She knew and they knew that it
was going to be the best and most supportive platform

(29:59):
for her to get started on this path. So again
I'll just be talking about how important it is to
bring us all together.

Speaker 15 (30:07):
I do really.

Speaker 14 (30:07):
Feel that community is community and people are the scaffolding
of longevity and super longevity medicine and the reason why
we're doing this. And so if you know what is
it that brought us all together, there's a little spark
that sparked in all of us that got us interested
enough in longevity beyond the health system that we know of,

(30:30):
and so that spark and what these organizations are doing,
it's really throwing fire at that you know, trying locks
at that fire, and making sure that they don't extinguish themselves,
that everybody gets seen and supported, and that there's this
African proverb that I really like that it says, if
you want to go fast, go alone, but if you
want to go further, go together.

Speaker 8 (30:52):
So that's what I'm going to be talking about today.

Speaker 5 (30:55):
Fantastic And I forget to say that Mariana was also
born in my name country, in Venezuela, and she's doing
incredible work.

Speaker 6 (31:04):
And the next year we are going to.

Speaker 5 (31:08):
Have the Work for Longevity, the March for Longevity in Washington,
d C. Yes, just like we had yesterday in Madrid,
but by by.

Speaker 14 (31:20):
Very big because numbers matter and visibility matters, and having
you know what you had yesterday, a full room of
people here makes such a big difference rather than just
having a few people. So imagine having hundreds of people
marching in d C advocating for longevity rights. And like
how we've heard from different people the option to be

(31:41):
able to obtain into some of these treatments and protocols
we've been talking about and learning about. So that is
something that we're working on, and we'll know in a
couple of months if it's ago, but we'll make sure
that everybody knows what. We're very excited about it.

Speaker 5 (31:55):
So now you know you all have to come and
join us in Washington, d C. For the March for
Longevity in the capital of the USA and some people
say the capital of the world. Anyway, let's finish with
my dear friend Cody Dean, who is the global ambassador
of a new fantastic initiative called immortali Is, and he's

(32:19):
from Florida, which is a beautiful state.

Speaker 6 (32:22):
Sonny in Florida Court.

Speaker 16 (32:24):
Thank you, Jose And yes, Florida is very beautiful and
I look forward to being at that march in Washington,
DC next year. I hope to see many of you there.
So I work with Immortalis, which is a global initiative.
We're very focused right now in the United States and
a South American country, both of which we're calling it
Niovia to be a little bit more agreeable to a

(32:45):
more conservative crowd. But what we're trying to do is
advocate for many of you who does have more of
that scientific background, because I don't have a scientific background,
But what I do have is a drive to live healthy,
much much longer than it's currently possible. So I have
been at events like Radfest supporting you for a long

(33:08):
long time. And when I finally connected with the founder
of Immortalis Mark Hamilton, who's over here, I knew I
had to jump on board with that because what we
are doing to help you, help us live is it's incredible.
What we're trying to do is unlock the funding that
so many of you desperately need. And part of the

(33:31):
way we're doing that is by accelerating some of the
regulatory pathways that are slowing things down. So when that happens,
investors will begin to see a better return on their investment,
both in profit margin and in timeline, and so you'll
see an influx of investment opportunity into you into what

(33:54):
you're doing when we successfully unlock a zone, and you'd
be surprised how close we are, even within the United States,
which has been historically tough to get into. So you know,
stay tuned for what's happening there could potentially be you know,
the end of the year early in the next year.
You know, politics is a very interesting landscape, so we'll see.

(34:17):
But once that is unlocked and you're able to come
in and do what you do much much faster and
with more funding behind you and still cheaper, you're going
to be able to save our lives faster, which is
selfishly what I want.

Speaker 5 (34:35):
So that's us fantastic Cody, and now I want to
go into a second round to see what they are
doing on their background is related to public advocacy because
part of the International Longevity Summit is to have an impact,
an impact on people, and you have seen we have

(34:56):
had two documentaries. We have been in all all the
media in Spain, you know, the media soon attacking us
by the way, they cannot understand that we believe that
this is science and technology that we are going to
be able to live longer, healthier, better. So I don't

(35:16):
understand how some people can attack this beautiful idea.

Speaker 6 (35:19):
But anyway, we are in all media, so.

Speaker 5 (35:21):
This is fantastic, all TVs, radio, newspapers. We had the
major of Madrid, I mean we can go much higher,
who is a very important person. And we had the
March for Longevity. We had a lot of things going on,
and we have fantastic speakers in all sessions, including these
beautiful planet So how can we move the movement forward?

Speaker 8 (35:44):
How can we impact? So this is the main idea that.

Speaker 9 (35:48):
Appears when a Parina Athinia was born. So in escent
Tom which is the vice president, myself and some other scientists,
we wanted really to have an impact, not only with
our research, but also to tell the society how important
is science. So if you pay attention to the richest
countries and the best countries in the world are those

(36:13):
which have invested a lot of money in science, and
because of these results that appeal. Finally they have an
impact and finally the society can really feel the impact
of this research. Something important that I would like to
mention is the importance of do research, do investigation in

(36:34):
every areas of knowledge. So the challenges we have in
front of us in this century and in the centuries
are really important and very big, and only through the
collaboration and interdisciplinarity of all areas of knowledge we can
give an answer to this to solve these problems. So

(36:56):
this is also something that we really focus on when
we are working in a paternal latentia.

Speaker 8 (37:04):
And this makes also very singular.

Speaker 9 (37:07):
Our associations, so you maybe see another different foundations, many
different associations that pay attention to one specific subject.

Speaker 8 (37:17):
In a paternal athentia, we pay attention to all.

Speaker 9 (37:19):
Areas of knowledge and this is something singular and also
as strength. Another singular part of patental things and one
of our strengths is that is leaded.

Speaker 8 (37:30):
And directed by scientists.

Speaker 9 (37:33):
So we are used to manage our group, lead our
group research groups and also we manage the We get
funding from many different funding agencies, not only national but
also international, and we know really which are the problems
and we know very well how with very little amount

(37:55):
of money to have an impact.

Speaker 8 (37:57):
In our research.

Speaker 9 (37:58):
That's why all the fundly we got we made open
calls and they have all the projects we receive, all
all the proposals are evaluated by scientists. That's why they
impact each much higher. So this is something that I
will want to share you because if you put money
in you, if you make a donation to a Padina Latinia,

(38:22):
you can be sure that all these money are going
to be optimized. It's not a waste of money, but
an investment in science, an investment to get results and
finally an investment to get an impact in the society.

Speaker 6 (38:38):
Thank you so stell here.

Speaker 10 (38:40):
So I prepare these graphics as I've been doing for
these conferences for the last few years. My name is,
as I said, Sergio Martinaterero, and I'm producing all these
videos on the streaming partly as a donation of a tourista.
I'll let you know that we're changing the logo. It's
a political party. I discussed and fired on these stages

(39:02):
of life picture. We just took you know, the part
after aging, because otherwise it would be too big of
us a logo. But I lived up there for now,
and yes I've covered just as part of this two
thousand and eight, Transmission, twenty one, twenty two, twenty four,
twenty five. Now my friends Jose David Wood and many

(39:23):
others go back over twenty years when I started documenting
events like the Forssight Institute conferences, then Transition two thousand
and six in Helsinki, twenty seven in Chicago with Charlie
cam I don't know if it's still here, and many
other such events. When I was growing up, I was
very concerned about the Cold War in the eighties. This

(39:44):
movie Wargames really touched me, and I thought very good
movies about important subjects could really change the world and
educate people. And everybody gets to hear about ideas to
the end of the world. Everybody knows Rocky Balb and
the Terminator, and you can really reach out with the

(40:04):
film medium. So when I was growing up, I thought
it was easier to influence the world through movies than
doing politics. I had never thought about going into politics
until much much.

Speaker 13 (40:14):
Later, many many years later.

Speaker 10 (40:19):
In two thousand and two or so, I was studying
how the Best incorporated the idea of my medical evolution
into a script. I inadvertently discovered transhumanism and the prospect
for molecular technology artificial superintelligence changing the world drastically in
a matter of a future decades. I decided to get
involved and to get informed, and to see what I

(40:40):
could do to help this movement to get us there
quicker but safer. I realized that the issues regarding these
ultra technologies like molecular nanotechnology and superintelligence were so grave
and so urgent, while at the same time so promising
and liberating, that I should focus more on how I
could influence their positive development while avoiding the worst risks.

(41:04):
Ever since, I have you know, recorded all these conferences
as part of my effort to help brow the movement
from all the ideas and make the videos look good
hopefully or better every year, and just to document them
for the record. After twenty ten or so, my thoughts
about super moral ais made me give a lot of
thoughts to the Way with three Animals, and I got

(41:26):
interested in animal ethics just to make friends and stuff
and to learn about it. I volunteered for an animal
rights political party, PATMA, and part of the animalist at
PATMA here in Spain for about a year. Then I
realized that something was missing in this party and basically
in every other political party which is a strong feminist component.

(41:47):
I'd witness political debates within the movement for about a decade.
They're very interesting and you know, enlightening and edifying, but
there was any being done. So I decided to start
the first political party with a few friends here in Spain.
Founding it was easy. Then we had to develop the

(42:08):
ideas further and it took time. It took years to
really develop our declaration of principles from a small document
into what it is today and we continued recording videos
and conferences are in twenty fourteen with an AI conference
in Santander were for later organized as well, and just
continued Crionist conferences and this and that, just many many things.

(42:31):
We had an unfortunate passing in the party, Havier with
the past, and we managed to honor his will of
getting him cryonically preserved. But yeah, the party kind of
revived and got new people in. And we also have a,
like I said, a strong animal latist component, and other

(42:51):
dimensions of political discussion that go beyond life extension. We're
also extremely concerned with big global catastrophic risk existential risks
that certain technologies could bring about, and so our Declaration
of principles grew. Let me see if I have just
an image of it. You should take a look at
the document yourself. Yeah, it's from something small to something

(43:15):
that's something like twenty five pages long today, and it's
we're pretty proud of it, and we wrote it every
few months. We have a new update. The last one
is just a few days old, so feel free to
take a look. Yeah, and I would like to read
briefly Kennedy's historian offs from Mars. In a recent email

(43:36):
from the Transhumitist Party in the US, he wrote this
short text. It's nice, so I'll just read it for you.
Aleantha Fatriista and the US Transumitist Party are the true
oldest transhumanist political parties in the world. We have endured
because we are guided by long term goals and enduring
vision of our transhumanist pursuits and transform the human condition

(43:57):
for the better, rather than focusing narrowly on winning election
or beating other political parties. Ultimately, transhumanism is a global
movement that leads to unite humans in our share aspiration
to overcome all age limits of mortality, disease, materialscustody, and irrationality. Therefore,
political success of trust humanists anywhere in the world is
a success for trusumanist everywhere in the world. Any jurisdiction

(44:19):
where transhumanism succeeds in influencing government policy in a direction
that is more open to technological advancement will be a
jurisdiction where research breakthroughs courrecture to benefit humanity. The US
TP considers aliataa Trista to be its key ally in Spain,
and we are eager to see what its efforts can
accomplished to enable Spain to become one of the foremost

(44:40):
prolengevity countries of our time. Ali Asafadrista is welcome. This
has to do with our suggestion that we would sign
their values document and that in our declarations they have
the Transhumitist Party Values and Trushumanists Bill of Rights, and
so we already passed it in our party work sign

(45:00):
this declaration and will add it to this part of
the website in the next few days. It's an announcement
I'm making as more of an interconnection between our two
parties because we should really strongly support each other. And yeah,
now just briefly, I would like to I would like
you all and everyone you know to help these parties,

(45:22):
to help Alianta to this die if you can to
get involved, to get to get to know us, and
there's memberships, there's you can make donations. There's a pretty
high limit in Spain for donations, so if anyone has money,
it can help us grow much faster, and especially human
force human you know members, especially within Spain, so I

(45:45):
know some of you are Spanish or people in Spain
are watching through the subtitles et cetera. So we need
people to have the different areas of the party. If
you like, if yours, especially an expert on any of
the fields we talk about, come to us so you
can head one of the departments or something like that.
And yeah, that's basically. I don't know if I have anymoreuslightes.

(46:08):
We were showing the Bill of Rights and all of
these things briefly, but yeah, there's a code if you
want to reach the website quicker.

Speaker 5 (46:15):
Thank you, okay, thank you Serkio for all you are doing.
And now we want to bring back the beautiful, the intelligent,
the expert on all of this, Sabini.

Speaker 15 (46:28):
Thank you, thank you.

Speaker 4 (46:30):
So are you all energized?

Speaker 17 (46:32):
Yes, yes, well we have a little energy left.

Speaker 15 (46:37):
We're going to have a few more speakers.

Speaker 17 (46:39):
Look at this eminent speaker panel sitting here, it's amazing.
I want to start off by introducing our next speaker,
who really has many engagements in longevity. Two of them
are as CEO of Balerno, the largest longevity clinic in
Europe that can host up to fifteen thousand patients, and also.

Speaker 8 (46:56):
CEO pro Jevita.

Speaker 17 (46:58):
I hope I can announce that a longevity retreat that
then is more geared towards business people and C suites.
And she's also the co founder of our ex Longevity,
a longevity coach app so she is truly, truly well
versed in the longevity space. Please give it up for
Clara Fernandez Porta.

Speaker 11 (47:24):
Hi, everyone, So when Jose asked me to talk about
public advocacy and how our clinic or our model was
working to help push the longevity science, I was very
happy to be here and be able to share you
how I have actually designed the clinic to make sure
that we could become a tool for society, for both

(47:47):
patients and scientists to push up longevity as much as possible.
So I have some slices. So just before you understand
and I'm gonna talk, I'm gonna be I have a
short presentation, but just be or I started telling you
a little bit more about my clinic, I want to
give you some context. So we're in Valencia, in the
middle of the forest. We have over two million square

(48:10):
meters in the middle of the forest, over eighty different buildings.
It is traditionally a historical thermal clinic, which in Europe
is very popular. So it was originally created to create
natural medicine treatment, but over the last thirty years the
company has evolved in the area of healthy aging and
health and longevity. So the company is actually founded by

(48:33):
it's a family company, so it's founded by my father
who is here a doctor, and as a family company,
we have been able to decide and create the strategy
that we thought would have the biggest impact in society.
We are initially focused on people from sixty to seventy
years because we believe that's in the longevity clinic ecosystem.

(48:55):
We believe that is the unique segment that has time
and willingness to dedicate themselves to that to longevity treatments,
and so that has enabled us to create a model
where patients come every day. We have an average of
sixty patients coming every day for ten days staying with us,
with six hundred patients as I mentioned, staying with us together.

(49:20):
And we have been able to create a framework of
treatments that I've been able to democratize longevity treatments. So anyway,
what I was going to tell you is how we
actually have created the ecosystem, because I think it's very
unique and very different to most of the other longevity clinics,
and that has been the core element that has given us.

Speaker 8 (49:41):
The unique advantage to.

Speaker 11 (49:42):
Both skill or super great. So here you can have
my information also my website. So first of all, the
most important thing that is different, Okay, I told you
so we have an average of one hundred and sixty
thousand patients per year daily patients. That makes us and
the biggest hotel in the province of Valencia, which is

(50:02):
a very touristic hotel. But what actually has the scale
and number of patients has given us is the possibility
to create accessible treatments. And why is this. Most of
the traditional longevity techniques that you know have a smaller scale,
and that makes that most of the cost of the
treatments are not necessarily uniquely the cost of medicine per se,

(50:25):
but the cost of the set up. So being big
is for us from a fundamental part of being able
to have a big scientific a big medical team, a
big scientific team and make sure that we can deliver
treatments at the unique marginal cost in terms of treatments.
Just so that you know, we're strong on red generative

(50:47):
medicine and anti inflammation protocols and patients can either come
to one of our set protocols that is a combination
of stem cell treatments or themolecular medicines, plasma therasis, ozone therapy,
or they can come to one of our personalized protocols.
All of our treatments do a combination of diagnostics, treatments,

(51:08):
and education. And this is also a very important part
that I want to make points on, especially as we're
speaking about public advocacy. Every patient that comes to our
clinic has an average of twenty hours of longevity master classes.
We are making sure that everyone that comes to our
space understands the biology of aging, not only what's available today.

(51:33):
We don't do this education or scientific master classes to
get them more treatments. For us, it is fundamental that
people understand the biology of their aging process and what
is to come in the next years, because we believe
that is the unique way that they're going to spread
the word and that they are going to have an

(51:55):
interest in taking care of their health. Yes, with raker Cell,
he told us in the presentation that he believes that
in just seven years when we might reach the longevity
velocity of escape. Well, that's fundamental that we teach society
because people are not going to take longevity treatments or

(52:15):
their health strategy in the same way if they believe
we are very far from having any impactful results in
our lives, or whether they think that is actually relatively close.
So economiest of skill enables us to have not only
great treatments delivered to the patient, but also to do
very specific master classes and make sure that we invest

(52:37):
in creating the education and the culture that we need
the patients to demand. Finally, because we have a lot
of patients, we have a lot of data. So it's
been almost I think eight years that we decided that
one of the biggest roles that we could have in
the longevity ecosystem was to become a plaque a platform

(53:01):
from scientists, for universities and for companies so that they
could actually research with our patient data, iterate their producals
with our patients, and finally be able to test the
final results. The Human Lab is a space where we
do clinical trials, but it's also a place where we

(53:23):
gather data for patients that we open for the science community,
just so you get a little bit of a scale.
This year we have had two point five million euros
in grants from government from Spain and from Europe. In
protocols that we have designed ourselves. We expect next year
to have more than three million and to double the
number of PhD students that are using our data to

(53:45):
publish scientific research. Also, we have created a model that
it's a digital biobank by which patients can actually leave
their data accessible for science. The data is going to
be sold different startups or companies, and that money is
going to be used as a unique wallet for the
patient that they can reinvest in their longevity treatments for

(54:09):
next year. I didn't mention this, but most of our
patients from every year, the protocols that we design are
designed to be a pit stop, an animal pit stop.
So they come every year, get checked up again, get
boosted with their motivation and their classes, what's happening in
in the biology of aging, make sure that they are
on the right track, redesign their plan and go back home.

(54:31):
So and finally, a human LAP is not just great
because we can push science, but because having access to
clinical trials enables us to deliver unique treatments under the
umbrella of clinical trials. So being in contact with the
scientific community is not just great to push the science,

(54:52):
but it also is the unique way to help us
be on the bank guard of what's happening in longevity.
So this isn't because of because it actually feeds himself
being able to have more clinical trials and unique clients.
It's actually what gives us the more patient base and
more people that are willing to come year after year,
which gives us more economies of scale and more data.

(55:13):
So this was basically the model I wanted to share,
and I think it's very relevant because most of the
longevitic clinics are not articulated in a way in which
they're interrelated to the scientific community, not just the science
that they're pushing themselves, but the general scientific community. And
I think this is a very important message to be
spread more of FAST could be making more treatments, more

(55:34):
democratized and having a bigger impact in society.

Speaker 15 (55:48):
Thank you, Clark.

Speaker 17 (55:49):
Really interesting to see as an ecosystem thinker, I mean
I found it very interesting. And our next speaker is
CEO for Digital for Health Worldwide and president of mad
eHealth flagship initiated and backed by Madrid City.

Speaker 8 (56:02):
Council, and his lifelong mission is.

Speaker 17 (56:05):
To really re architect healthcare around the patient, so be
patient centric, fusing public and private integration, open innovation, and
also AI into everyday care and digital health. And with that,
I'd like to hand the word over to Carlos dis Lsa.

Speaker 13 (56:23):
Thank you so much.

Speaker 12 (56:31):
I have shared something very important with you guys a
few minutes ago. You remember when I told you I
was a very bad student brings a bell. I was
a horrible student. Actually I lied to you. It was horrible,
not bad. But I was doing something, you know, what
I was doing very well, just one thing. Can you

(56:52):
think of what I was doing, just one thing, dreaming
one thing and trying to do it well. So I
spent hours, if you think of university long hours, long studies,
so I spent long hours, as all of you did,

(57:13):
probably dreaming. And today I'm going to share with you,
hopefully one of my last dreams. I've had a lot
of nightmares by the way, also, but this is one
of my last dreams that I have shared with you before.
So this video is a very simple example of what
I dreamed eight years ago, when, as I said before,

(57:36):
we were trying to put together public and private sectors
because we all think that healthcare doesn't have to be
public or private.

Speaker 13 (57:45):
It has to be good.

Speaker 12 (57:47):
And as far as I know, the only possible way
for us to deliver a very good healthcare healthcare system
is by unifying, putting together both sectorsublic and private. Let
maybe before we see the video, just say this a
very little piece of thought.

Speaker 13 (58:06):
So you know healthcare systems.

Speaker 12 (58:08):
So public is probably seventy percent of the total in
volumes in values. But we need a private and private
needs public. Are we ready, so let's go for it? Well,

(58:41):
there is no noise.

Speaker 7 (58:45):
Yes, there is.

Speaker 1 (01:01:37):
Gee that gave me so.

Speaker 12 (01:01:47):
Come back, gave you.

Speaker 15 (01:01:50):
Say it all.

Speaker 13 (01:01:59):
And thank you so much.

Speaker 12 (01:02:09):
So this is, as I said before, our last but
not least dream. We keep dreaming. This is the first
digital city in the world. We have two campuses. Eight
thousand square meters is the first one, more than one
hundred square meters for the second one. We have invested

(01:02:30):
more than six hundred million euros, which is a lot
of money. We are welcoming and I am in discussions
with the owner of this event, with mister Cordeo, because
I would really love to keep dreaming, and I dare you,
all of you to keep dreaming.

Speaker 13 (01:02:50):
I would like to make.

Speaker 12 (01:02:52):
This city the center of the European longevity world. We
should think of it. Nothing stops us from thinking and
from dreaming. So this is our contribution. You were asking before, Louis,
what is our contribution to this longevity. I am not
a doctor. I was a Hord student, as I told

(01:03:14):
you many times. But we think that putting together private
and public is fundamental. Dreaming is fundamental. Integrating all stakeholders
is fundamental. As I said before, we are not in
heathcare only one. There is no one decision maker. We
have many in this sector. By bringing them together and

(01:03:36):
making them work together, we can improve. This is our
contribution to longevity. Thank you so much, thank you, thank you, thank.

Speaker 8 (01:03:50):
You so much.

Speaker 17 (01:03:51):
And next up we have head of Outreach and Marketing
at the Coalition for Radical Life Extension, a non for
profit providing education, resources and community for longevity. So please
give it up for Marianna Deceellis.

Speaker 14 (01:04:14):
Thank you. I don't have slights, but I do want
to address your question, Jusse. Right after we introduce ourselves,
what can we do to advocate for ourselves or what
can we do? Do you want to said that question, Joset,
because I'd really want to answer it. Well, I'd like

(01:04:34):
to say, Okay, so I do want to answer that
question that you gave us, because so, yeah, I told
you about the Coalition for Radical Life Extension. We spoke
about RADFAST, the Rally for Longevity Rights. The coalition is
also has launched this year it's global initiative, and this

(01:04:55):
global initiative wants to take radfast and beyond and really
clearly create the platform for and just bring advocacy and
breage the gap between policy and people and bringing the
funding for actually age reversal, not just extending human life span.
And then I really let's keep it personal here because

(01:05:17):
we're all people who here. Whether you feel longevity or
immortality for yourself, you feel something more. And so I
want to ask you which one of you feels like
you have an advocate or are advocating for yourself on
a daily basis?

Speaker 15 (01:05:32):
Anybody?

Speaker 14 (01:05:33):
Nobody? Okay, So doesn't that make you feel a little like, oh,
I don't have anybody advocating for me today? Am I
advocating for myself today? And so what we're doing, what
I'm doing with the Coalition and with people Limited, which
I feel so proud of, is that we've really brought
together people like Jose has done that here, we've done

(01:05:56):
that in this panel. How you've done the car with
the clinic and Sarah here and how you've done it
also encoding as well in all of our panel here.
It really bring people together to remind ourselves and support
each other and really are pursuit for this more health?

Speaker 15 (01:06:13):
And so what is worth?

Speaker 14 (01:06:15):
What it's longevity if you're not going there with anybody?

Speaker 15 (01:06:18):
Right?

Speaker 14 (01:06:19):
And what do we do when we feel we don't
feel as supportive, we feel sad or we get bad biomarkers?

Speaker 15 (01:06:24):
Who do you tell?

Speaker 14 (01:06:26):
And what do you do after the event over here tonight?
And so because you feel this boost, you feel excited,
you feel seen. I've seen from ten years of working
with Radfast and almost twenty with People Limited, I've seen
researchers and scientists come into that room feeling sad because

(01:06:46):
they've been unfunded, they don't feel seen because the research
feels too out there. And then they come in into
rooms like this and meet people like you, and then
they feel seen. They find somebody that will find them
because maybe I know somebody else, But that only happens
when we get together. And so really we've heard about
all of the tools that we talked about. However, said

(01:07:08):
let's throw all the tools together. And I really quite
agree with that, and what are those tools if we're
not you know, what are we doing with these tools?
And I really feel that community and spirituality really makes
sense of those tools, because then other than that, you know,
they're just tools. And so I feel that community really
puts together not only the purpose, but what we're doing

(01:07:29):
with those that sense.

Speaker 7 (01:07:33):
What can we do?

Speaker 2 (01:07:34):
I don't know.

Speaker 14 (01:07:34):
I think we all have an answer to what we
can do for longevity. I think we all have very
valid answers. I think on this Cove has a very
beautiful answer. I think Clara has very beautiful answers. David
would present that aful beautiful answers. I think we all
have very valuable answers to what we can do to
advocate for super longevity, age reversal, and immortality. But I

(01:07:56):
can tell you what you can do for me with
us so that we can help you. I think you
need to show up like you have here. We need
to show up to events like this. We need to
show up to radfast, we need to show up online,
we need to show up in person, people Limited needs
twice a week. I've been meeting twice a week for
eighteen years with people like you that want this, and

(01:08:21):
we meet online or in person. We have people that
have joined us from all over the world, in Africa
and Asia and all over and these are all people
like you who are very passionate and really want to
see this come through. And so I really invite you
to show up to come and join me. So for
people Limited that websites people limited ink dot com, for

(01:08:43):
Radfast that's ratfest dot com, for the Global Initiative, and
what we're doing with the coalition, that's our l E
Coalition dot com. And if you have any questions you
can come and ask me.

Speaker 15 (01:08:55):
Thank you, Marianna.

Speaker 17 (01:09:02):
I think that was a perfect way to sort of
show that we need a humane aspect when we also
talk about longevity, and especially when we talk about advocacy,
because each and one of us are an advocate for
our own health, there is a sense of sovereignty needed
and this can then have ripple effects.

Speaker 4 (01:09:19):
And I think community and.

Speaker 17 (01:09:20):
Role models are key because we're talking about health. I mean,
we've been talking about that since, you know, since the
Stone Age, because we all want to live healthy, but
I think we need to have a common vision. Why
do we want to live a long, healthy life? Well,
presumably not in the way the world looks today. So
there's so many factors, and I think community is a

(01:09:40):
really important one. Infrastructure is another one. But let's hear
more from a law speaker, Cody Dean, who is an
entrepreneur and public voice in immortality and longevity culture, especially
as content creator for the Immortalists.

Speaker 8 (01:09:55):
So please give it up for Cody.

Speaker 7 (01:10:01):
Thank you.

Speaker 16 (01:10:03):
But I also did not come prepared with slides, so
I apologize for those of you who are visual. You're
going to have to just power through and listen. Here.
I want to address the question that Jose posed earlier
before we started these presentations of how do we move
this movement forward? And if you really boil it down,
there's a challenge of supply and demand, which seems simple enough,

(01:10:24):
but how do we break that down a little bit more.
There's a few aspects to this. There's the problem of science,
which many of you are working on, so you know
there's that, But why is science why has it not
achieved a cure to aging and most of these age
related diseases yet? Is it just because the science isn't there.

(01:10:45):
That's a questionable thing. But if we look a little
bit further back, there's a challenge of funding, which many
of you have addressed and asked about and talked about.
And there's also a challenge of potentially outdated policy and
politics at play here.

Speaker 7 (01:11:02):
But if you take.

Speaker 16 (01:11:03):
Another step back, you can see there's an element of
this is where the demand comes in. It's people who
want it. You know, we see this crowd here and
there's a decent number of people watching live and virtually
around the world, and you know, up to hundreds of
people who show up to Radfest and Aubrey's event in Dublin.

(01:11:25):
You know, there is a community for this, but the
demand is not to a level where the voice is
heard loud enough to affect change on a political and
policy level. And if that were to happen, if enough
people were to advocate, and this is where the public
advocacy comes in, we all need to be louder, we

(01:11:46):
all need to talk to more people, and in doing so,
that voice becomes more unified. I've given an analogy before
of a symphony. How many people have seen the symphony before?
Or I at least know what that is, so you
probably at least know what a symphony is when you
go to a concert, and if you haven't been, just
imagine you walk into the auditorium similar to this, and

(01:12:08):
down in this area is a large orchestra with lots
of different instruments, and when you get there early enough,
you see them all warming up. The conductor is off
the stage and everyone's warming up their instruments, getting tuned.
And if you look down and you pay attention to
the flutes, you can kind of hear what the flutes
are doing. Their scales is very high pitched, very airy,

(01:12:32):
and then there's also a cacophony of sound that's secondary
behind that because you're focused on the flute section. But
then you shift your attention over to the French horns
or the trumpets or whichever other instrument, and now that's
what you hear. You hear them doing their scales, and
you hear the tone and the tamera of that instrument,
and then again just a cacophony of sound that the

(01:12:54):
flutes have now blended into. And when you don't focus
on any instrument, it's just a cacophony of sound. Don't
really hear any particular thing. But when the director comes
back out and stands at the front and brings his
hands up, the entire orchestra comes to attention. And when
the director moves his hands and the song starts, now
all of a sudden, you hear a unified piece of

(01:13:15):
music and it's beautiful. And that's how we need to
imagine this community and this movement. We need to come
together and unify that voice so that way it is
heard as one song, and that will be beautiful and
it will be heard by the audience, the policy makers,
the regulators, the governments around the world, and when it's heard,

(01:13:38):
they understand that we as a community, as a people,
not just a longevity of community, but a human community.
We are the voter base, so they're going to listen
to us if they want to keep their jobs. So
when that happens, policy can be adjusted and streamlined in
order to maintain safety and efficacy, which we we absolutely need.

(01:14:01):
Nobody wants fraudsters coming into this space selling snake oil
and killing a bunch of people because they want to
make a bunch of money on longevity. We definitely need
a standard of safety and efficacy, but we can streamline
regulation so that we were not holding back beneficial therapies
for ten to fifteen years that could be saving lives

(01:14:22):
much sooner because they can prove themselves much faster. So
when that policy can be streamlined and adjusted, then investors
see the potential if they see their potential investment having
a higher profit margin and having that return come back sooner.
And that's why in a space like what we're doing
with Neovia, we want to have a proof of concept

(01:14:46):
in a city model first and then of course expand
from there. We'll have a sister city in South America,
and then maybe eventually one here in Madrid. You know,
who knows what the future potential holds there. Even just
starting with one proof of concept, we see that we
will see that this streamline regulation is going to speed

(01:15:09):
up processes. It's going to make more investment come in.
But parallel to more money coming in and funding your projects,
there's also going to be a reduction of the cost
to go through those trials because there won't be as
much regulatory red tape to go through, and the regulation
that is there is actually there to promote safety and efficacy.

(01:15:31):
We'll have positive regulation and streamline way through it with
approval processes that happen as trials are happening, and are
tailored to each therapy and trial that you're trying to do,
because in this space there are so many different things
with genetic editing, with a cellular rejuvenation, with stem cells,

(01:15:52):
they all require a different way of looking at it
and proving it safety and efficacy. That one blanket finition
of that can't be used to cover everything, and that's
a big challenge we're running into. So as more funding
rolls in and as the cost of trials come down,
then we'll finally reach that point where we're five to

(01:16:13):
ten years away or three to five years away from
having a major breakthrough in curing age related diseases and
ending humans suffering as a result of that is actually
going to be three to five years away, as where
we are now. We've heard three to five years, we've
heard five to ten years, we've heard ten to twenty years.

(01:16:36):
For the last forty or fifty years, we need to
get to a point where three to five years means
three to five years on the slow end. We think
we could make things happen much much faster, and that's
what we plan on doing. But the major goal is
to open up the funding opportunities, the investment opportunities, into

(01:16:57):
your scientific community, into the trial as you are doing again,
like I said earlier, because selfishly, I want to live
and I want to be healthy. I don't want to
grow up older and then die from being sick or
just getting old. Because we're just dealing with the things
we're dealing with now. So how do we move this

(01:17:17):
movement forward? To break it down to the most simple thing,
advocate talk to people that demand will through as I
just discussed, hit all the different points where finally the
supply will have to be there.

Speaker 4 (01:17:33):
Thank you, Thank you to all of you great advocates.

Speaker 17 (01:17:44):
Does anyone have any questions when it comes to advocacy
because this is actually a topic that relates to each
and every one of us, so you know, no questions
are too small.

Speaker 4 (01:17:57):
Oh you know, could we just have a short does
mad what the question was in English?

Speaker 15 (01:18:02):
So maybe the audience not I one in Spanish?

Speaker 14 (01:18:07):
I think I think you were asking about that all
tel question on whether.

Speaker 15 (01:18:13):
You know what happens?

Speaker 14 (01:18:15):
You know, do you distribute money first to guns or
do they go to fiting? And how do we and
what are kind of alliances are we going to make
sure to make so that we know that that money's
been distributed?

Speaker 5 (01:18:27):
Right?

Speaker 14 (01:18:29):
If I can take that question first, I will say,
until we solve aging, there's always going to be worse.
I mean, I think there's always going to be death.
But once we cure aging, there's going to be a
huge culture shift. I mean, we're looking at the biggest
paradigm shift we've ever seen has humanity. And unfortunately people

(01:18:50):
see death like part of a circle. That's not how
I feel, that's not what I see. I feel differently.
But once we cure death and the diseases of aging,
the whole paradigm that we've known so far as humans
and culture are completely going to change. So the question
we posed so far and the way we've treated each
other so far are going to change. Because if you're

(01:19:12):
not just getting rid of ten years worth of living
of a human, you're getting rid of five hundred years.

Speaker 17 (01:19:18):
So yeah, hopefully we're expanding our consciousness and seeing other
things worthwhile than what we've seen in the last decade
of man hurting man.

Speaker 5 (01:19:28):
Yes, actually Spanish scientists who got the Nobel Price and
Teago Ramonica help so he gave classes here. By the way,
Santiago Ramonica Hall lectured here our first Nobel prize in
nineteen o six or something like that.

Speaker 6 (01:19:46):
I was not born at the time.

Speaker 15 (01:19:48):
There we have one.

Speaker 18 (01:19:49):
I think you have to make a ratio between how
much money is spent in health and in weapons per
year for Washington and the radio property is going to
be two minutes of defense expenditure in one year is
less than what we're spending here.

Speaker 17 (01:20:08):
Yeah, we need the politicians at the table so we
can ask that question.

Speaker 6 (01:20:14):
Marianna.

Speaker 5 (01:20:14):
Since you are organized in the march, they're running in Washington,
d see, what are you going to tell President Trump.

Speaker 15 (01:20:24):
I'm not going to.

Speaker 14 (01:20:24):
Answer that, but I will answer is that the march
is focusing on longevity rights because we don't want this
to be something that can be used against us.

Speaker 15 (01:20:35):
We spoke about safety and security before.

Speaker 14 (01:20:38):
So one of the biggest focus of the Coalition and
the March is going to be to really make this
about everybody and not just about longevity and immortality, but
really about all of us being able to get access
to all of this medicine. And we feel that that
it will be the first door to open and then
all of this will be because I also have the
same concerns as we do. So I'm glad you're putting

(01:21:00):
that out there.

Speaker 15 (01:21:02):
Any more questions.

Speaker 17 (01:21:04):
I mean, all of you are are advocates, So if
we would sort of summarize and maybe hand the tool
of advocacy to people.

Speaker 8 (01:21:11):
Here, if you could each share, you know, your own sort.

Speaker 17 (01:21:14):
Of nugget on advocacy. How do how do we create
a narrative around longevity? I mean some say immortality, some
say radical life extensions, some say hell, some say living forever.

Speaker 4 (01:21:27):
You know, if we're going to unify this advocacy, if
each and.

Speaker 17 (01:21:31):
Every one of you know, did you have like a tagline,
and then we can get some inspiration when it comes
to longevity or eternal living, flourishing.

Speaker 4 (01:21:40):
Joy, spam, whatever it might be.

Speaker 5 (01:21:44):
Yeah.

Speaker 8 (01:21:44):
Well, to finish, I'm going to be a little bit
more general.

Speaker 9 (01:21:47):
So my main advice I cannot avoid to give advices
because I'm mother for two daughters and one son, and
I used to do advices.

Speaker 8 (01:21:59):
So my many advice is to support science and to
pay attention to scientists.

Speaker 9 (01:22:05):
It's very important to have critical thinking talking about longevity,
about health, about many other things. We pay attention to
people that really don't give advices support it by science data.
So this is very important to develop the critical thinking.
So this is one of my first advices. The other

(01:22:28):
one is as a citizen, we can really support companies
that support science instead many other things like.

Speaker 4 (01:22:37):
Weapons or whatever.

Speaker 9 (01:22:38):
So we should develop also our critical thinking to see
which companies we like and we don't, So this is important.
And for the companies, I will advise you to use
your responsibility to support science for example through a patinal,
a TENTFIA and as a citizens also I mean something

(01:23:01):
that we want to be to be.

Speaker 8 (01:23:05):
Happy, to be healthy and happy. And one that of
the things that make us very happy is the generosity.
So when you find a course, you find a purpose
in your life and you really support it by a
donation or by a collaboration with it. So we are
here to have you. You are happy and finally you

(01:23:29):
are you are better in life.

Speaker 9 (01:23:32):
So please I hope many of you find a paternal
athenia a good way to really put your donation or
do your collaboration to support science that finally is going
to impact in.

Speaker 8 (01:23:45):
All our lives.

Speaker 9 (01:23:47):
And also you have the possibility to reduce the taxes
because a parentalth Infia.

Speaker 8 (01:23:52):
Got the position of Tilda public. So please you are
welcome to come to visitors. I think, thank you.

Speaker 7 (01:24:02):
I just want to.

Speaker 10 (01:24:02):
Support her idea. It's the law of life is really
what defines the community. We love life so deeply, we
really want to extend it. We find it extremely unfair,
and I think.

Speaker 15 (01:24:13):
It's not hard to drive this feeling into everyone.

Speaker 13 (01:24:16):
We really I think that the problem is most people have.

Speaker 10 (01:24:19):
Not heard that this is even possible. Honestly, most people
that I talk about it with and just regular people,
most people are supportive of life extension. And I think
it's more of a marketing and a media effort. And
as soon as we all everybody realizes life is so valuable,
so important that who wants to kill each other to
have arguments, to have fights to discuss silly political part

(01:24:43):
also the trend of the right and the left, and
so we're so sick of it that we have to
move past this period. It's really annoying and frustrating that
the debates are not more more enlivening.

Speaker 17 (01:24:57):
There needs to be a mirroring the weapon here in
health here, and there's a mirror because everybody wants initially
what you're saying, But we're living in a world where fear.

Speaker 10 (01:25:05):
And scarcity is but nobody knows what transhuman is.

Speaker 13 (01:25:07):
Amiss.

Speaker 17 (01:25:08):
Yeah.

Speaker 11 (01:25:11):
On a similar tone, I don't tend to speak to
my patients about immortality, but I always try to ask
them like, do you want to die tomorrow? They usually
say no, and then it comes like what makes you
think that you will want to die someday if you're
a great health. So I think that for the general

(01:25:31):
society talking about infinity immortality, it's just like concepts. They
can really grass no exactly, but when they put it
into the perspective of today, no one wants to die tomorrow,
and eventually that means that you don't want to die
at some point if you're in great health. And as
we're talking about advocacy and I don't want to extend
because I know it's too long, I would love to
make a small remark, especially going back to the science part,

(01:25:54):
that we need to do more research on female longevity definitely.
So it's if longevity has little funding, female longevity as
lost to none and women age differently than men exactly.

Speaker 15 (01:26:10):
So as an.

Speaker 11 (01:26:12):
Advocate and having a microphone in my hand. This fun
female research, female angevity research.

Speaker 17 (01:26:19):
And to add to that, there is something in the making,
the launch of Superwoman, which is going to be dedicated
just to that. So I'm really getting all the women
I can find to get together and make that happen.

Speaker 12 (01:26:32):
As I said before, we need to keep pushting, developing
and fostering public and private collaboration because we need a
better system that prevents, not just cares what prevents.

Speaker 13 (01:26:45):
Thank you.

Speaker 14 (01:26:46):
I think we cannot be afraid of spirituality and the
divinity of the body, and we need to remind each
other of that. I think that when people think of
cure and aging, they think you're trying to play God.
And I don't see anything wrong with that statement.

Speaker 15 (01:26:59):
I think we are and I think we all here.

Speaker 14 (01:27:03):
Of something in common, and it's that we do all
feel the value of human life, of our bodies and
some other people's bodies that we've lost, and so for
all of us to not forget why we're doing this,
and it really is the celebration of the divinity of
the body.

Speaker 13 (01:27:20):
Thank you.

Speaker 16 (01:27:21):
To go back to the original question of immortality versus
radical life, extension versus longevity, and how do we combine
all of that. To me, the common denominator is do
you want to live healthier, longer period. If the answer
is yes, you're a part of this community. After that,
it's a personal choice on the individual level of how

(01:27:42):
much longer.

Speaker 17 (01:27:42):
Do you want? And I really think, you know, I
think that the purpose is also we need to find
purpose and meaning in our own lives and in sort
of the life in general. And I think when we
start to navigate, whether it's spirituality, divinity, I mean, these
concepts are getting much more into the life now. A
few years ago when you spoke about this, it was
a bit woo woo, but this is actually, you know,

(01:28:05):
self evolvement. We're here for a great adventure called life.
Of course, we want to live, enjoy and happiness, but
we also need to be sovereign and start to maybe
demand that.

Speaker 4 (01:28:13):
And it comes from you know, the people.

Speaker 17 (01:28:16):
And longevity is an amazing, amazing, you know occurrence that
it's happened now because advocacy has never been stronger, because
people are voicing up. The science is there, and I
think it's going to you know, accelerate more and more
thanks to people like you.

Speaker 4 (01:28:31):
So round of applause for all of our advocates.

Speaker 11 (01:28:33):
A leader is thank you.

Speaker 6 (01:28:38):
Thank you.

Speaker 17 (01:28:43):
So with that, ladies and gentlemen and advocates of longevity
and pioneers, our final keynote speaker is truly a pioneer herself,
both as a leader how she came into the longevity space,
which many times happen because you have a person issue
with which she had with her son. But she's a
pioneer within gene therapy and one of the boldest voices

(01:29:06):
in the field as well, because she allows also to
be provocative.

Speaker 4 (01:29:10):
Not Lisa's gene therapy.

Speaker 17 (01:29:12):
As we know, is not accessible, but she's really traveling
the globe around to really make this accessible in certain
parts of the world. She's the founder and CEO of Bioviva,
a driven humanitarian entrepreneur and a leading voice for genetic cures,
and she's championing gene therapies as a path to human rejuvenation.
And here we can talk about human trials because she

(01:29:35):
is doing this on herself. Please give it up if
she's with us, Liz perish.

Speaker 15 (01:29:42):
Hopefully, Okay, fantastic.

Speaker 3 (01:29:49):
It's nice to be here everyone, and so let me
get my slides ready.

Speaker 15 (01:29:54):
I have the Hi Jose how are you awesome?

Speaker 3 (01:30:00):
I just okay, great, I can share my slides. It
looks like and so we'll get on that. I hope
everyone's enjoying the conference. It looks like you guys had
a terrific March two for the Death of Death, so
fantastic and congratulations on that. Okay, fantastic. So we're going

(01:30:20):
to talk about the evolution of gene therapy, where we've
been and.

Speaker 15 (01:30:24):
Where we are going.

Speaker 3 (01:30:25):
As you know, Bioviva has had a little bit of
a rocky road this year because of what's called hands
off research.

Speaker 2 (01:30:36):
Hi.

Speaker 3 (01:30:38):
I can see everyone in the audience. Hey, everyone, whoo,
shake it up, get your body moving. I know it's
evening for you, but it's early in the morning for me.
You guys all look fantastic, So let me proceed in
hands off research. What we do is we pay a

(01:30:58):
university to do research, and then sometimes there are things
called detractors, and sometimes there are things called missteps in science.
And right now we have a paper that's under review
for just that.

Speaker 15 (01:31:11):
And I imagine the infernos.

Speaker 3 (01:31:13):
Of hell are going to be burning bright in the
near future for one side or the other. So we
can't talk too much about that today because that's under investigation.
But I'll let you know that our company is dedicated
to science and science working for humans. We are translational
engine and that's what we're going to get into today.

(01:31:36):
If science can't translate to humans, then we are all
going to die. And I'm going to show you how
we have proven that science has already translated and that
we can build upon it.

Speaker 15 (01:31:47):
But if we are detracted from.

Speaker 3 (01:31:49):
And science is blocked, that would be the responsibility of
the murder of millions of people.

Speaker 15 (01:31:55):
And so we also have to watch that side of
the aisle.

Speaker 3 (01:32:00):
Let's get into an exciting presentation in which I think
you can all.

Speaker 15 (01:32:05):
Agree we need the cure aging.

Speaker 3 (01:32:08):
So we're going to go back really quick historically into
the death records of humans.

Speaker 15 (01:32:13):
And this is because I want to show you that
science is already working.

Speaker 3 (01:32:17):
We have basically elucidated many different scientific advances to extend
human lifespan.

Speaker 15 (01:32:25):
And these records are evidence of that.

Speaker 3 (01:32:27):
So in sixteen sixty five, we vastly died of infectious disease,
and because we took it so seriously, by the year
of nineteen hundred, we got that infectious disease rate down
to almost fifty percent of the population. And that was
because we used science, a technology that's rigorous that tests
whether or not something will work to circumvent maybe in

(01:32:51):
this case, a death outcome. And this is fantastic because
this made it so that we could live longer and healthier.

Speaker 15 (01:32:59):
But if you notice graph, we start to see the.

Speaker 3 (01:33:03):
Expansion of diseases that we didn't have on the original graph,
and that is because we started to.

Speaker 15 (01:33:11):
Name aging associate diseases.

Speaker 3 (01:33:14):
So by the year twenty ten, only three percent of
the population is dying of infectious disease.

Speaker 15 (01:33:20):
And this is science.

Speaker 3 (01:33:21):
This is science showing that already it's working on life expansion.
So longevity science started way back, probably around the eighteen
hundreds and has advanced beautifully since then. So if people
say that it is science fiction to extend lifespan, actually
most of the population has already benefited from that.

Speaker 15 (01:33:44):
So when we look at.

Speaker 3 (01:33:45):
Old medicine, we looked at symptom management, and we still
have a lot of this, mostly in the healthcare system,
not so much in medical tourism. But we do what's
called symptom management, and we use tools and we look
at herbal remedies and natural things that we can do,
and this is really still where diet and exercise lies.

(01:34:07):
It's powerful technology and you can see that it got
us a long ways. Then as we advanced, we worked
into diagnostics. How did we actually diagnose something before it
happened instead of waiting for it to happen, And this
really opened the realm of regeederative medicine to step in.
And that is really the third stage, which is using

(01:34:28):
regenerative medicine to create a cell that stays in homeostasis,
that ages as slowly as possible, or maybe even reversus aging.

Speaker 15 (01:34:37):
So I'm going to talk about.

Speaker 3 (01:34:39):
Our modalities of how we work, and we work at
Bioviva in genetics and in gene therapy. So our mission
is to find gene therapies that will modulate the aging
process and keep the body in homeostasis. How I became
a GMO and why I think you will too was

(01:35:00):
a long journey that I've had over twelve years in
regenerative medicine in ten years with the company Bioviva, and
the evidence that we've shown that probably actually working with
genetic therapeutics is the best way to move forward for
most of the population because then you can set a
lot of your biological aging therapies and forget them at

(01:35:22):
least for ten to fifteen years.

Speaker 15 (01:35:24):
And that's an unimaginably powerful tool.

Speaker 3 (01:35:27):
We will probably need other tools alongside this technology, and
we'll talk about those as we go. So why I
became a GMO is I was working regenerative medicine for
two years and my son was diagnosed with type one
diabetes in twenty thirteen.

Speaker 15 (01:35:43):
So after working in the regenerative medicine.

Speaker 3 (01:35:45):
Space, I thought that once I ended up in the
hospital or a loved one did, that this regenerative medicine
technology would be available for us, that we would not
be fighting diseases with palliative care.

Speaker 15 (01:35:59):
But in fact I was wrong.

Speaker 3 (01:36:01):
This type of technology was not translating quickly, not quickly
enough for most patients on the hills of Going to
a SENSE conference later that year to meet the professor
of genetics at Harvard, George Church, which eventually joined the
company as a founder, I found out that by treating
biological aging and treating the genetic basis of biological aging,

(01:36:23):
we could actually expedite cures for these kids. And so
my company, Bioviva, every gene we have chosen since then
will actually treat both ends of the spectrum, so the
aging population and the young population, basically taking care of
the critical care for the most.

Speaker 15 (01:36:39):
Vulnerable populations on the planet.

Speaker 3 (01:36:43):
And why do we need to do that because both
vulnerable ends of the population drain a lot in resources.

Speaker 15 (01:36:52):
So when you're young, you.

Speaker 3 (01:36:53):
Don't have a job, makes sense, society pays for you
to grow up. Then you're in your earning stages, in
wh you are profitable in the sense that you're above
what it costs to live, and then as you age, unfortunately,
you fall back below this line. And this is really
critical because many people who are in this age group

(01:37:14):
of around fifty five still have dreams.

Speaker 15 (01:37:17):
There are still things they want to do. But these
estimates in earning versus.

Speaker 3 (01:37:22):
Eating would tell us that your dreams are over and
you better breaks for the future of really high costs
and healthcare.

Speaker 15 (01:37:31):
We want to change that. So what does that look like.

Speaker 3 (01:37:34):
Let's go back to sixteen sixty five. Infectious disease. You're
going along, you get an infectious disease, you die fast.
The middle graph is what happens today. That is the
death curve, the slow death curve, and decline into in
stage diseases, and what happens is you get a symptom
and then we try to recover you with today's medicine,

(01:37:56):
but generally we put you back on the death curve
and your health continues to decline, but you continue to
consume these drugs that at least keep you alive. The
graph on the right we call tomorrow's medicine, but it's
already started about ten years ago when we started. And
this is what happens when we look at genetics, the

(01:38:19):
ability to potentially restore the body to a healthy state.
I was just at Harvard with David Sinclair a couple
of days ago, and he has amazing research also going
on in gene therapy. Some of the things that we
do it bio viva as well, and incorporating all of
these things looks incredibly promising to maybe deliver on this

(01:38:42):
graph that I'm showing you.

Speaker 15 (01:38:44):
So what is gene therapy.

Speaker 3 (01:38:46):
With gene therapy today, we use AAV It's a deno
associate virus. It is what used to be a virus
and it's now attenuated and called a vector.

Speaker 15 (01:38:56):
It can no longer get you sick.

Speaker 3 (01:38:58):
But what's really great about these vectors is nature has
designed them eloquently to deliver to your cell's genetic material
to the nucleus for long term expression. So we can
take something that used to get you sick and turn
it into something that delivers healthy genes that are required

(01:39:20):
for sustained gene expression of youthful bodies. And basically we
call that a regain of function and a restoration to
healthy and therapeutic benefit of these genes. So what you'll
see is it delivers that gene sequence into the nucleus
of the cell and then it's transcribed and it creates

(01:39:41):
a protein. And those proteins are what make you up.
So those proteins are very important for the health of
your body. They're given by IV, intramuscular injection, intranasal injection,
organ delivery directly, and there are some gene therapies that

(01:40:03):
are given topical for children with rare skin disorders.

Speaker 15 (01:40:06):
We don't do topical gene therapy at this point, but
we do every other type of delivery.

Speaker 3 (01:40:13):
Actually, this is an image that was just pulled because
it was a beautiful image, but actually that's a lot
what gene therapy looks like. It's a clear liquid I
think a lot of people wonder what their injection would
look like, and it is a clear liquid and not
very scary.

Speaker 15 (01:40:31):
But very wonderful.

Speaker 3 (01:40:35):
Now Here is where we're going to show the benefit
of gene therapy. That's already happening. So on the left side,
this boy has muscular dystrophy and he's trying to climb stairs.

Speaker 15 (01:40:46):
And the first place that full of.

Speaker 3 (01:40:50):
Statin, the gene full of statin that's now often used
in medical tourism for an aging population was used was
Induchines and Becker's muscular dystrophy. And this was one of
the patients. This was him three months after gene therapy.
Now we're hypothesizing that patients over the age of seventy
will also need a secondary gene therapy that we're going

(01:41:12):
to start using with fullostatin to increase their muscle mass
and strength due to other delterious effects of biological aging.

Speaker 15 (01:41:20):
And so you're going to hear about that soon.

Speaker 3 (01:41:23):
But already we have showed a myriad of successes in
patients with this gene. Again, according to studies and Chemophilia B,
with this delivery method, patients thirteen years later are still
showing expression of gene function, So that's fantastic. So, first

(01:41:45):
of all, the area of gene therapy started in fixing
underlying genetic problems, and this is where it really went
to show its major successes and what made us realize
that it had the propensity to problem treat diseases that
are more complex in order. And these are the therapies

(01:42:09):
that are already approved in the gene therapy space.

Speaker 15 (01:42:12):
So if you think that this is up and coming technology,
it is not.

Speaker 3 (01:42:16):
It's already approved by the FDA for thirteen therapies. So
these are all the therapies that are available now. They
come with an enormous price take because when you treat
a small population, you create a very expensive technology. But
by treating biological aging, we could actually make making these

(01:42:39):
type of therapies just free for young patients and patients
who just need to come up to the line of
stability with the rest of the population. Preventative medicine is
probably the best place for gene therapy in those conditions
that I just showed you. You could consider the gene

(01:43:01):
therapy itself a preventative medicine that keeps those children from
having the outcome of those diseases. If we catch patients earlier,
we will probably have much more benefit with gene therapy,
and so I believe that as this technology is shown safe, it.

Speaker 15 (01:43:18):
Will be used with younger and younger patients.

Speaker 3 (01:43:24):
On the longevity side, what we can do today is
we can lengthen your tilomeres. We have so many patients
data now that shows that we can do that, and
that's wonderful, and that includes the shortest tilomeres, which are
very important to target.

Speaker 15 (01:43:39):
We can increase muscle masks. Definitely.

Speaker 3 (01:43:41):
I did not work out today, so I'm probably not
all pumped up, but that is something we can do,
and that is a beautiful consequence of follostatin gene therapy.

Speaker 15 (01:43:53):
Now in aging patients who are over a certain.

Speaker 3 (01:43:57):
Age who don't have precursor stem cells, we are still
waiting to see how well we can do cognitive enhancement.

Speaker 15 (01:44:04):
We can accomplish this. I don't want to make any claims.

Speaker 3 (01:44:09):
Here, but when we do alpha CLOTHO gene therapy, we
have seen an average increase in a standard deviation of
IQ tes on IQ tests and that's pretty powerful because
that could take people who are really low on the
spectrum and make them more functioning, and people who are
really high, well it can make them even more awesome. Okay,

(01:44:33):
so we need more of those people. So kidney protection,
that is something that we can do with two gene therapies.

Speaker 17 (01:44:42):
That we have.

Speaker 15 (01:44:44):
Mitochondrial therapy. We have a therapy that is specifically for that.

Speaker 3 (01:44:49):
We are working into five new candidates that we will
be launching in actually the next six months and getting
the first human data on, and they all benefit minochondria
as well. Cardiovascular protection is something we can do with
one of our gene therapies, metabolic health. Several of our
gene therapies target metabolic health. Nerve regeneration is something in

(01:45:13):
the process, and there's a wonderful gene that is associated
with re scaffolding. Also, there is evidence that the OSK
factors benefit.

Speaker 15 (01:45:24):
Nerve regeneration as well.

Speaker 3 (01:45:26):
And then of course epigenetic reprogramming that's been all over
the news and we have our own proprietary form of
doing that.

Speaker 15 (01:45:33):
Okay, all right, it's fun to be home because I
can kind of play around here. So sorry, I've got
too much energy for you.

Speaker 3 (01:45:39):
So in ever changing world, we need to genetically modify
to basically survive the future, survive a dying of death
and disease, and Jose is definitely behind the crusade to
make sure that you are aware of our enemies.

Speaker 15 (01:46:00):
Environment is also an enemy. Living in extreme conditions is
also an enemy, and so we need to work towards that.

Speaker 3 (01:46:10):
Enhancing and continual repair is critical for us to get
the most out of life. We definitely want to stick
with being able to get out and do the things
that we love. And I am a huge proponent of
gene therapy for that integrating technology. Sam Altman was talking

(01:46:30):
about how they're looking for genes now to basically help
integrate technology into you, making it so you don't have
to maybe lose your devices. Your devices might become part
of your body. This is fantastic and exciting. And then
of course exploration of different environments. We know that going

(01:46:52):
to space causes accelerated aging. We know that the detriments
of deep atmospheres also caused damage to our body, and
so we want to make sure that we're on top
of that and that we don't limit where we can
go and who we can go with. So now I'm
going to talk about some human data, and all of

(01:47:15):
this will be my data, because right now I don't
have permission from patients to release their data. But I
want to show you what we can do now and
what we have seen, not just in my body, but
in other people's bodies as well. So years ago we
released a paper on my data. We showed that since
my first gene therapy and my second gene therapy which

(01:47:37):
gave me a little bit of a boost of telomeri's
reverse transcript case. This is a gene therapy that lengthens
the caps at the ends of the chromosomes. These shortening
of these caps are associated with a myriad of disease.

Speaker 15 (01:47:52):
As a matter of fact, all the diseases of.

Speaker 3 (01:47:54):
Aging and critically short telomeres lead to increase risk of
genomics instability, which causes cancer. There are a lot of
different things that I can tell you, but this would
be a talk all on its own. Since my gene
therapy is in twenty twenty five, my tilomere length has

(01:48:18):
lengthened by an average of five point three years for
every year I've lived, and my tilimeres are longer since
these results, and I need to get this year's tilomere
test done so then we'll have twenty four and twenty
five and then a release more information.

Speaker 15 (01:48:35):
Very important short tilomeres in your immune system, which are
the tilomeres that we actually test.

Speaker 3 (01:48:43):
Short tilomeres were associated with deaths in COVID nineteen. Number
one association was immune senescence.

Speaker 15 (01:48:52):
Whether you're young or you're old, you need.

Speaker 3 (01:48:55):
To have cellular division in the immune cells or they
cannot divide to attack an infection. So it goes beyond
just chromosomal stability and living longer in certain benefits of that. Also,
things like lobsters and certain clams, they may be living

(01:49:17):
as long as they do, which is in extremely long
time hundreds of years due to having to lameris turned
on in every cell. So I am a proponent of this.
We have not seen drawbacks or adverse drug events, and
we've watched patients for over five years.

Speaker 15 (01:49:35):
Full of satin.

Speaker 3 (01:49:36):
We can increase our muscle mass as long as you
have precursor stem cells, and we'll be able to increase
your strength even if you don't. And we'll talk about
a company that is going to help replace those stem cells.

Speaker 15 (01:49:47):
Anyway, this is my results that were put out.

Speaker 3 (01:49:51):
This is my MRI image and my muscle mass increased,
and my intramuscular fat went down. Full of statin comes
with a bunch of benefits. If you look at the
literature review around it, it's kind of crazy. It helps
with tissue repair, regeneration, It turns down inflammatory markers. We

(01:50:12):
believe that re establishing the immune system is dependent on
turning down these markers. That the things that we used
to think actually major immune system really strong, which was
stressors and inflammation, actually keep it from rebuilding your body.

Speaker 15 (01:50:28):
And I'm working with a.

Speaker 3 (01:50:30):
New company that's going to be showing that in human
data over the coming year and a.

Speaker 15 (01:50:34):
Half, So this is really important.

Speaker 3 (01:50:37):
It may actually even have a protective role that's full
of statin in prostate and breast cancer, and that's something
that we're going to want to watch and see. And
of course, increase muscle mass is associated with insulin sensitivity,
which is vital to not have type two diabetes. Again,

(01:50:58):
we will have growing evidence there. When we talk about
brain health, we often talk about alpha CLOTHO and one
of the things that my company wanted to do starting
in maybe two thousand and sixteen or seventeen after I
was treated, is learn how to redose aav We're the
only company in the world that can do it that

(01:51:20):
we know of, and we wanted to prove that we
were having a therapeutic effect even with redosing events. So
on the left side you see my alpha CLOTHO levels.
This was after I had already been treated in twenty twenty.
But what it shows is that I'm in the ninetieth
percental for alpha CLOTHO for my age, and that's fantastic.

Speaker 15 (01:51:44):
That means the first gene therapy probably worked.

Speaker 3 (01:51:48):
Then we did a redosing protocol and on the right
side that is an increase to the ninety fifth percental
for alpha clotho.

Speaker 15 (01:51:57):
And since then, I think my school or because we.

Speaker 3 (01:52:00):
Did it again, I just keep doing it and now
it's one thy three hundred and I think twenty eight.

Speaker 15 (01:52:10):
So now I'm basically hovering in the top area.

Speaker 3 (01:52:14):
I don't really want to go over that where we
want to get the alpha clotho in the maximum area.
We don't want to take it over what would be
natural for a human homeostasis at this point, so I
will be working on some other.

Speaker 15 (01:52:30):
Data years ago.

Speaker 3 (01:52:32):
Let's see, this was in twenty twenty one we launched
a paper of a safety study with h turt and
alpha CLOTHO and patients with dementia and we saw a benefit.
And I actually took this to the US FDA and
did a pre I ind on it, and they asked
for eight million dollars worth of animal studies even though

(01:52:52):
we had human data. So that was at the point
that we tipped, and we started licensing out to other
companies who could use it in the locations they were in,
or could they had the aptitude and the fortitude to
raise the money to get into the US FDA. And
I'm happy to tell you we've got new two new
groups coming on to use this therapy and patients with dementia,

(01:53:14):
one in the US and one in the Bahamas.

Speaker 15 (01:53:16):
But we'll talk about some more coming up here. But
what happened.

Speaker 3 (01:53:20):
Cognitive scores went up and biological age went down.

Speaker 15 (01:53:25):
It was not a cure, but it did offer.

Speaker 3 (01:53:28):
Hope for some of these patients, and one patient went
from living in assisted living to living on their own.
We really want to work this towards a medical cure.
These were incredibly low doses. We're hoping with higher doses
and the insertion of a third gene that we want
to use, we're going to get better results. So what

(01:53:52):
happens if we keep curing mice, but we can't get
things to humans. As you know, all of you probably
know not get into this industry to do research and development.
I got into this industry to help patients, and that's
why scientific.

Speaker 15 (01:54:07):
Accuracy is so important for me. We're a different beast.

Speaker 3 (01:54:11):
We believe that if you've got good medicine, you'd be
using it, and if you're not, we're going to put
you to the challenge of getting it up there.

Speaker 15 (01:54:20):
I've spent about a third of my time in regulations.

Speaker 3 (01:54:24):
I worked in a myriad of zones, one zone that
actually approved their regulations last year to use gene and
cell therapy, and I will continue to push for new
innovative areas to open up for the use and access
of these technologies, including the United States. We work with

(01:54:45):
several concierge medicine companies, and these are healthcare companies that
basically you're given a special person who handles your dossier
and they help you get access to technology.

Speaker 15 (01:54:58):
All over the world. This is a Swiss group.

Speaker 3 (01:55:00):
They have clinics in Switzerland and we also work with
clinics all over the world with gene and cell technology
and almost anything that is very high value that would
be hard to get through a normal system. We also
have these four licensing partners on top of a couple
other ones. We've just added. Future Health is in China.

(01:55:24):
They're a fantastic group. They're starting to work with a
Chinese government in ninety two hospitals to move technologies forward.
On the upper right side is an Unlimited Bio. They've
been working in Honduras and they treated a Kardashian. Hey,
that is really cool. They're a cool group, very cool group.

(01:55:44):
On the bottom left is Integrative Health Systems. They have
treated over three hundred patients without an adverse drug event
and knock onward. We're very proud of them and they're
an incredible group of thirteen medical doctors and a concierge
system that helps with all the pre impost and all
the travel arrangements.

Speaker 15 (01:56:03):
And on the bottom right is a group I was
going to talk about. That's re gen Cell.

Speaker 3 (01:56:07):
They're working on replacing your stem cells, but not just
replacing your stem cells, reprogramming them and adding genetic function
to them. And so you're going to hear more about
them over the next couple of years. And that is
a super benefit because for people over the age of
sixty five, they're down to five percent of their stem cells.

(01:56:30):
And without these stem cells, you cannot regenerate your body.
So these are very very important cells to the body.
So they need to be replaced. And if they're reprogrammed first,
that's a benefit. And if they have better gene function,
even cooler. So I know that we move quickly, but
we are an engine for change. We are humanitarian group

(01:56:55):
of scientists, medical doctors and business people who believe that
we need to spend our time for the betterment of humankind.
And so I want to leave you with this quote.
He who rejects change is the architect of decay. The
only human institution which rejects progress is the cemetery. I

(01:57:17):
suggest you don't land there. Thank you so much, thank you,
thank you very much.

Speaker 17 (01:57:31):
Liz.

Speaker 5 (01:57:32):
We we love you, but we have to say goodbye,
good bye, goodbye, thank you, thank you, bye bye.

All Episodes

Episode Transcript

Popular Podcasts

On Purpose with Jay Shetty

Ruthie's Table 4

The Joe Rogan Experience

.css-15opob5{left:0;position:absolute;top:0.8rem;} All Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}TransVision Madrid 2025 Summit

Episode Transcript

Popular Podcasts

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}On Purpose with Jay Shetty

Ruthie's Table 4

The Joe Rogan Experience

All Episodes

TransVision Madrid 2025 Summit

On Purpose with Jay Shetty